Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung ...

The results from the post-hoc analysis identified that pirfenidone may be an effective treatment in progressive fibrosing uILD over 24 weeks, irrespective of ...

In the RELIEF study of patients with progressive fibrosing ILDs other than IPF (connective tissue disease-associated ILD, fibrotic non-specific ...

(PDF) Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial ...

Approximately 12–13% of patients with interstitial lung disease (ILD) are diagnosed with unclassifiable ILD (uILD), often despite thorough ...

Pirfenidone in patients with unclassifiable progressive fibrosing ...

This study found that pirfenidone was associated with benefits in lung function and exercise capacity compared with placebo after 24 weeks of treatment, thus ...

Phase II Trial of Pirfenidone in Patients With Progressive Fibrosing ...

The primary objective of the study was to evaluate the efficacy of pirfenidone vs. placebo using change in FVC (mL) measured by daily home ...

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung ...

Approximately 12-13% of patients with interstitial lung disease (ILD) are diagnosed with unclassifiable ILD (uILD), often despite thorough evaluation.

Pirfenidone in patients with unclassifiable progressive fibrosing ...

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

Safety, tolerability, and efficacy of pirfenidone in patients with ...

Compared with the placebo group, patients in the pirfenidone group had a slower rate of decline in lung function, measured by estimated annual change in ...

Pirfenidone in patients with unclassifiable progressive fibrosing ...

Introduction Despite extensive multidisciplinary team (MDT) assessment, some patients have interstitial lung disease (ILD) that is ...

Pirfenidone in Unclassifiable Interstitial Lung Disease - SpringerLink

A numerically beneficial treatment effect for pirfenidone versus placebo on FVC change was observed regardless of previous corticosteroid use in ...

Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases ...

Pirfenidone-treated patients had a significantly lower decline in FVC% predicted compared with placebo-treated ones (p = 0.043). However, due to the premature ...

Interstitial Lung Disease: A Review - JAMA Network

In a clinical trial of 253 patients with unclassifiable ILD randomized to either pirfenidone or placebo for 6 months, pirfenidone reduced FVC ...

a randomised, double-blind, placebo-controlled, phase 2 study

Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, ...

Pirfenidone in Progressive Pulmonary Fibrosis - ATS Journals

Conclusions: Pirfenidone use in patients with PPF is associated with a statistically significant decrease in disease progression and with ...

Pirfenidone in patients with unclassifiable progressive fibrosing ...

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, ...

Home spirometry to assess efficacy of pirfenidone in progressive ...

Finally, the 24-week mean change in 6-min walking distance (6MWD) also favored pirfenidone over placebo. ... Importantly, no new concerns were raised with regards ...

design of a double-blind, randomised, placebo-controlled phase II trial

Introduction Despite extensive multidisciplinary team (MDT) assessment, some patients have interstitial lung disease (ILD) that is considered unclassifiable ...

efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic ...

The morbidity of idiopathic NSIP is only inferior to IPF among the idiopathic interstitial pneumonias. The efficacy of corticosteroids on f- ...

Phase 2 Pirfenidone Trial Indicates Potential Effectiveness in ...

Pirfenidone, sold as Esbriet, was shown to potentially benefit patients with progressive fibrosing unclassifiable interstitial lung disease ...

Home spirometry to assess efficacy of pirfenidone in progressive ...

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double- blind, randomised, placebo-controlled, phase 2 trial.